DDW 2015: Sofosbuvir + Daclatasvir for 12 Weeks Cures Most HIV/HCV Coinfected Patients

Kenneth Sherman from the University of Cincinnati presented findings from the Phase 3 ALLY-2 trial, which evaluated Gilead Sciences’ nucleotide polymerase inhibitor sofosbuvir plus Bristol-Myers Squibb’s NS5A inhibitor daclatasvir without ribavirin.
Daclatasvir is available in Europe and Japan and is currently awaiting U.S. Food and Drug Administration approval. Gilead’s Harvoni coformulation contains sofosbuvir plus its own NS5A inhibitor, ledipasvir. Unlike ledipasvir, which is active against genotype 1, daclatasvir is more pangenotypic, meaning it works against multiple HCV genotypes.

Manufacturers asked to qualify regulatory needs for hepatitis C drug registration

The Drugs Registration Board in Pakistan has decided to develop further guidelines for local manufacturers to qualify the minimum regulatory requirements for hepatitis C drug registration at the earliest by its next meeting in June 2015

Statement of HIV Constituency, CSO Forum on Asia-Pacific Forum on Sustainable Development (APFSD)

Statement of HIV Constituency during CSO Forum on Asia-Pacific Forum on Sustainable Development (APFSD) 2015

Summary of generic sofosbuvir availability in India

Summary of generic sofosbuvir availability in India and pricing as of 18 May 2015.

Regional Consultation on access to Direct-Acting Agents for hepatitis C treatment

With this consultation convened by TREATASIA, we hope that we will be able to clearly understand the anti-diversion measures that have been promoted by pharmaceutical companies to prevent the resale of anti-hepatitis C drugs and strategic ways to respond to these measures and increase community awareness of their potential negative impact on treatment access and implications for patients’ rights. We also hope we will have the opportunity to understand how the voluntary licenses are being implemented for Sofosbuvir, the recent rejection of a related patent application in India and consequent appeals, timelines for initiation and scale-up of generic production, and pricing negotiations within the region.

ICAAP 12: Will it happen?

Bangladesh is speeding its preparations. The country is clearly taking the current conference as the best opportunity to introduce itself as the destination of the 12th ICAAP. Many suggested that ICAAP12 to be posponed.

Transition from CCDU to voluntary community-based treatment and services

The aim of this consultation is to build on the results of the previous Regional Consultations and provide input, advice, data, and examples of country practices in the formulation of evidence-based recommendations to support the transition from CCDU to a more comprehensive system underpinned by voluntary community-based treatment options and a range of complimentary health and social services that are aligned with international guidelines and principles regarding drug dependence treatment, drug use and human rights.

Key populations global consultation on reaching the 90–90–90 HIV treatment targets

More than 100 stakeholders from around the world met at UNAIDS headquarters to develop recommendations to help realize the 90–90–90 HIV treatment targets. The ambitious targets by 2020 are to ensure that 90% of all people living with HIV will know their HIV status, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90% of all people receiving antiretroviral therapy will have viral suppression.

Adoption of the Economic and Social Commission for Asia and the Pacific Intergovernmental Meeting on HIV and AIDS

The Meeting requests that the Commission at its seventy-first session consider, with a view to endorsing, the report of the Asia-Pacific Intergovernmental Meeting on HIV and AIDS, which was held in Bangkok from 28 to 30 January 2015

CSO Intervention under Agenda 4 at the IGM on HIV

This was a four minutes intervention read by representative of CSO during IGM on HIV and AIDS 28 January 2015